Malignant Hepatobiliary Neoplasm Clinical Trial
Official title:
Pilot Study of Ponatinib in Biliary Cancer Patients With FGFR2 Fusions
This pilot phase II trial studies how well ponatinib hydrochloride works in treating patients with biliary cancer that has spread to other places in the body and that have alterations (fusions) in a gene known as fibroblast growth factor receptor 2 (FGFR2). Ponatinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
PRIMARY OBJECTIVES: I. To assess the clinical benefit rate (confirmed complete or partial response or stable disease for 4 or more cycles) of ponatinib (ponatinib hydrochloride) in fibroblast growth factor receptor (FGFR) aberrant advanced biliary cancers. SECONDARY OBJECTIVES: I. To estimate progression free survival, overall survival, and cancer antigen 19-9 (CA19-9) response rate of these patients. II. To estimate the adverse event profile of ponatinib. TERTIARY OBJECTIVES: I. Establish preliminary correlations between FGFR2 fusions and evidence of any clinical benefit. II. Assess preliminary evaluation of FGFR2 pathway perturbation with ponatinib. III. To describe patient-reported health-related quality of life and symptoms. OUTLINE: Patients receive ponatinib hydrochloride orally (PO) once daily (QD) on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up every 6 months for at least 2 years. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02916199 -
Primary Needle Knife Fistulotomy Versus Conventional Cannulation Method
|
N/A | |
| Completed |
NCT05068739 -
Needle Knife Fistulotomy Versus Partial Ampullary Endoscopic Mucosal Resection for Difficult Biliary Cannulation
|
N/A | |
| Recruiting |
NCT06053333 -
Social Determinants of Health in Hepatobiliary Cancer Patients
|
||
| Not yet recruiting |
NCT03195075 -
Endoscopic Ultrasonography Guided Biliary Drainage
|
N/A | |
| Recruiting |
NCT03857958 -
Metal Versus Plastic Stent in Malignant Hilar Biliary Obstruction
|
N/A | |
| Completed |
NCT03112668 -
Acceptance and Commitment Therapy in Improving Well-Being in Patients With Stage III-IV Cancer and Their Partners
|
N/A | |
| Recruiting |
NCT04704661 -
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
|
Phase 1 | |
| Recruiting |
NCT05334069 -
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
|